MGLL, monoglyceride lipase, 11343

N. diseases: 125; N. variants: 7
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.050 Biomarker phenotype BEFREE Among these additional components, the endocannabinoid-degrading enzymes fatty acid amide hydrolase and monoacylglycerol lipase, lipid transport proteins of the fatty acid-binding protein family, additional cannabinoid-activated G protein-coupled receptors such as GPR55, members of the transient receptor family, and peroxisome proliferator-activated receptors were identified as targets for possible strategies to combat cancer progression. 31143113 2019
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.050 Biomarker phenotype BEFREE Functionally, macrophage MGLL inhibits CB2 cannabinoid receptor-dependent tumor progression in inoculated and genetic cancer models. 29968710 2018
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.050 AlteredExpression phenotype BEFREE Finally, we analysed the association of MAGL expression status with tumour progression, tumour thickness and vascular invasion of the primary lesion. 28681540 2017
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.050 AlteredExpression phenotype BEFREE Monoacylglycerol lipase (MAGL), a critical lipolytic enzyme, has emerged as a key regulator of tumor progression, yet its biological function and clinical significance in hepatocellular carcinoma (HCC) is still unknown. 27884159 2016
CUI: C0178874
Disease: Tumor Progression
Tumor Progression
0.050 Biomarker phenotype BEFREE Monoacylglycerol lipase (MAGL) is a key enzyme in lipid metabolism that is demonstrated to be involved in tumor progression through both energy supply of fatty acid (FA) oxidation and enhancing cancer cell malignance. 27767105 2016